GEN Exclusives

More »
New Products

Related to Eppendorf, Vela Develop Nucleic Acid Extraction Platform

    • Automated Benchtop Cell Sorter
    • Bio-Rad
    • The S3 is a cell-sorting system for core facilities and individual research labs. It is designed to ease bottlenecks by serving as a supplementary instrument for basic cell-sorting work. Equipped with one or two lasers (488 nm and either 561 or 640
    • Digital PCR System
    • Bio-Rad
    • The QX200 Droplet Digital™ PCR system provides quantification of target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications. The QX200 system includes droplet generator, droplet reader, laptop computer, software, and associate
    • PCR Reagents
    • Thermo Fisher Scientific
    • Phusion Green High-Fidelity DNA Polymerase and Luminaris Color qPCR master mixes utilize tracking dyes that are meant to speed up the pipetting process. By providing a visual confirmation, the mixes are designed to reduce the chance of human error
    • Reverse Transcriptase Kits
    • Bio-Rad
    • Two iTaq kits have been introduced for reverse transcription quantitative PCR (RT-qPCR) applications. They are designed for use under most reaction conditions on any qPCR instrument. The kits include the iTaq universal SYBR® Green one-step kit
    • Automated Microplate Dispenser
    • BioTek Instruments
    • The MultiFlo FX offers up to four independent reagent dispensers and a washer in one platform. Designed to automate microplate-based liquid handling processes, the MultiFlo FX can be used for 6- to 1,536-well plates. It allows a choice of peristalt
  • Page 1 of 1 (5 items) 1 

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?